

## Wenn «selbstgemachte» Biologika krank machen: Immundefekte durch Anti-Zytokin-Autoantikörper

### Lorsque des molécules biologiquement actives de l'organisme rendent malade: Déficits immunitaires induits par des auto-anticorps anti-cytokines

#### Literatur / Références

1. Smolen JS, Emery P. Infliximab: 12 years of experience. *Arthritis Res Ther.*2011;13 Suppl 1:S2.
2. Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience. *Aliment Pharmacol Ther.*2011;33(8):857-69.
3. Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. *Ann Rheum Dis.*2013;72(4):482-92.
4. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. *N Engl J Med.*2012;366(13):1190-9.
5. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. *N Engl J Med.*2010;362(2):118-28.
6. Donath MY, Storling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T. Cytokines and beta-cell biology: from concept to clinical translation. *Endocr Rev.*2008;29(3):334-50.
7. Browne SK, Holland SM. Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms. *Lancet Infect Dis.*2010;10(12):875-85.
8. Remus N, Reichenbach J, Picard C, Rietschel C, Wood P, Lammas D, et al. Impaired interferon gamma-mediated immunity and susceptibility to mycobacterial infection in childhood. *Pediatr Res.*2001;50(1):8-13.
9. Chi CY, Chu CC, Liu JP, Lin CH, Ho MW, Lo WJ, et al. Anti-IFN-gamma autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1\*16:02 and HLA-DQB1\*05:02 and the reactivation of latent varicella-zoster virus infection. *Blood.*2013;121(8):1357-66.
10. Browne SK, Zaman R, Sampaio EP, Jutivorakool K, Rosen LB, Ding L, et al. Anti-CD20 (rituximab) therapy for anti-IFN-gamma autoantibody-associated nontuberculous mycobacterial infection. *Blood.*2012;119(17):3933-9.
11. Puel A, Doffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. *J Exp Med.*2010;207(2):291-7.
12. Kisand K, Boe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. *J Exp Med.*2010;207(2):299-308.
13. Burbelo PD, Browne SK, Sampaio EP, Giaccone G, Zaman R, Kristosturyan E, et al. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. *Blood.*2010;116(23):4848-58.
14. Al Khatib S, Keles S, Garcia-Lloret M, Karakoc-Aydiner E, Reislil I, Artac H, et al. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome. *J Allergy Clin Immunol.*2009;124(2):342-8, 8 e1-5.
15. Puel A, Cypowyj S, Marodi L, Abel L, Picard C, Casanova JL. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. *Curr Opin Allergy Clin Immunol.*2012;12(6):616-22.
16. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. *Sci Transl Med.*2010;2(52):52ra72.
17. Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. *N Engl J Med.*2003;349(26):2527-39.
18. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. *Am J Respir Crit Care Med.*2002;166(2):215-35.
19. Dranoff G, Crawford AD, Sadelain M, Ream B, Rashid A, Bronson RT, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. *Science.*1994;264(5159):713-6.
20. Suzuki T, Sakagami T, Young LR, Carey BC, Wood RE, Luisetti M, et al. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. *Am J Respir Crit Care Med.*2010;182(10):1292-304.
21. Kitamura T, Tanaka N, Watanabe J, Uchida, Kanegasaki S, Yamada Y, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. *J Exp Med.*1999;190(6):875-80.

22. Leth S, Bendstrup E, Vestergaard H, Hilberg O. Autoimmune pulmonary alveolar proteinosis: treatment options in year 2013. *Respirology*.2013;18(1):82-91.
23. Puel A, Picard C, Lorrot M, Pons C, Chrabieh M, Lorenzo L, et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. *J Immunol*.2008;180(1):647-54.
24. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3 mutations in the hyper-IgE syndrome. *N Engl J Med*.2007;357(16):1608-19.